Regeneron and ModeX Forge Potential $1 Billion+ Collaboration to Develop Multispecific Antibody Drugs

Regeneron Pharmaceuticals and ModeX Therapeutics (an OPKO Health company) announced a new license and collaboration agreement to develop multispecific antibody drugs for several mutually selected therapeutic indications2 4 7.

ModeX will apply its MSTAR platform in conjunction with Regeneron's proprietary antibody binders to create candidates that target multiple biological pathways within a single molecule2 4.

The collaboration starts with a $7 million upfront payment to ModeX, and includes future product selection, clinical, regulatory, and commercial milestone payments that could exceed $200 million per selected molecule2 4 5 7.

If multiple products progress successfully through development and commercialization, the overall value of the agreement could surpass $1 billion2 4 7.

ModeX is eligible for tiered royalties based on global net sales, reaching up to low double digits at higher tiers2 4.

Regeneron will fund and lead preclinical studies, clinical development, and commercial operations for any chosen antibody drug candidates2 4.

Targeted therapeutic areas for the multispecific antibodies include immunology, oncology, and metabolic diseases4.

Sources:

2. https://www.globenewswire.com/news-release/2025/10/29/3176387/0/en/OPKO-Health-s-ModeX-Therapeutics-Enters-into-Research-Collaboration-with-Regeneron-to-Develop-Multispecific-Antibodies-for-Select-Therapeutic-Indications.html

4. https://www.stocktitan.net/news/OPK/opko-health-s-mode-x-therapeutics-enters-into-research-collaboration-6ztd8ml5cavu.html

5. https://www.pharmabiz.com/NewsDetails.aspx?aid=182122&sid=2

7. https://trial.medpath.com/news/d5a50b07739f4b2f/modex-therapeutics-and-regeneron-partner-on-1-billion-multispecific-antibody-collaboration

Sources:

Leave a Reply Cancel reply